Parasitic Diseases List

[unable to retrieve full-text content] 'On the verge of death': man sues Horry County jail over untreated ...    Myhorrynews

Transcriptomic analysis of primary hepatocytes infected with P. cynomolgi schizonts To gain insight into the host response during the liver stages of malaria, previously published RNA sequencing datasets obtained from primary simian hepatocytes infected with P. cynomolgi [9, 10] were aligned to a reference host genome and used to quantify the expression of host genes in comparison to naive cells from uninfected samples (see Methods). More precisely, P. cynomolgi -infected hepatocytes were cultured for 6–10 days and subsequently FACS-purified, yielding GFP-expressing hypnozoites (GFP-low) and schizonts (GFP-high). These samples were then compared to naive uninfected cells using RNAseq. Preliminary results showed that while samples infected for 6–7 days were associated with only few statistically significant differentially expressed genes, samples infected for 9–10 days were associated with numerous statistically significant changes in comparison to uninfecte

A woman who had recently traveled through Central and South America discovered a botfly larva wriggling out of a sore on her arm five weeks later. According to the case study, published in the British Medical Journal , the anonymous woman had two lesions on the left wrist, which she said developed after she had been bitten by a mosquito. "In the first week I felt extreme itchiness and shooting pains down the length of my forearm. Over the first two weeks, the bumps grew and remained red/inflamed. The itchiness started to subside, but the pain continued. "Pus and a clear, yellowish liquid would leak out of the two bumps, and the bumps were hard to the touch. I never saw anything move, nor was I suspicious of anything growing under my skin," the patient wrote in a Patient's Perspective section of the BMJ paper. Stock image of human botfly larvae. A woman who was traveling across South and Central America found two larvae inside a boil on her arm five weeks after retu

Dec 29 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) said on Thursday its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study. Data from the study showed that a single dose of the therapy was superior to the current standard of care in helping reduce the bleeding rate in patients with moderately severe to severe forms of hemophilia B. The disorder hampers the body's ability to make a blood-clotting protein called factor IX. Pfizer's therapy, fidanacogene elaparvovec, is designed to help patients produce factor IX themselves after a one-time treatment, as opposed to current treatments, which focus on regular infusions of the protein. The drugmaker licensed its hemophilia B gene therapy from Roche's (ROG.S) Spark Therapeutics unit in 2014 for a $20-million upfront payment. Pfizer plans to discuss the late-stage data with regulatory authorities in Europe and the United States and share additional

Photo courtesy of Wikipedia. "Humans are not Hobbits" — This I agree with, but I disagree with the reflection that was printed on Nov. 16 claiming barefootedness as objectively unacceptable. It is my intention to prove that the author has a right to question what she sees, but her arguments fail to take account of the situation's reality. Firstly, the author unreliably presents "science-supported reasons" with an argument that starts with an emotionally driven claim that being barefooted is "plain disgusting." I find no objective evidence for this. The author tries to support her claim with hookworms being problematic. However, she fails to recognise that there have only been eight reported cases in Texas since 2018; and I am sure we can agree that people are not defecating on UD soil, which is how the parasites are introduced. Additionally, the argument relies heavily on hyperbole. The Mall

In a study of patients with hemophilia A (HA) in Thailand, researchers identified improvements in clinical outcomes after patients were switched from a factor VIII (FVIII) concentrate product with a standard half-life (SHL) to a product with an extended half-life (EHL). These and other study findings were recently published in a report in the journal Haemophilia . Use of EHL FVIII concentrates having a median of 1.3- to 1.6-fold longer half-life, compared with SHL FVIII concentrates, potentially may reduce prophylactic dosing from 3 to 2 times per week, the researchers explained in their report. However, there may be variation among patients in the dose of EHL FVIII concentrate that is needed. The research team conducted this study to identify outcomes with low-dose FVIII prophylaxis using PK-guided EHL FVIII concentrate dosing after use of SHL FVIII concentrate. The single-center, prospective study (ClinicalTrials.gov Identifier: NCT05281185) included Thai patie

A man has been dragged online for telling his pregnant wife she must clean the cat litter box. In a post on Reddit's r/AmITheA****** sub, which already has more than 23,000 upvotes, user u/mozzz22 shared his reasons. "My wife and I are expecting our first baby. Three years ago my wife decided she desperately wanted a cat. I hate cats and all animals in the house so I was against it," he explained. "She wouldn't stop talking about it so finally we made a deal she could get a cat but it was her responsibility—I would have nothing to do with it." A stock image of a cat litter box with a scoop, left, and a picture of a pregnant woman looking out of a window, right. The internet has slammed a husband for refusing to clean the little box while his wife is pregnant. axelbueckert/kjekol/Getty Images The couple stuck to their word and the woman cared for the cat while the Redditor admits he mostly ignored the animal. But now she is pregnant, things have changed

Rubella and rubeola — also known as German measles and measles, respectively — are both contagious viral infections that appear with fever and then a rash. The names and symptoms of these infections are similar, so it can be difficult to tell the difference between them. Both infections are most common in young children but can also occur in adults. Infections are less common now, thanks to vaccines developed in the 1960s. But they can still be dangerous, especially to infants and young children. In this article, you will learn how to tell the difference between these two viral illnesses, what each rash looks like, when to expect other symptoms, and how you can prevent and treat these infections. Both rubella and rubeola are viral infections. Rubella, also known as German measles, is an infection by the rubella virus. Rubeola, often referred to simply as measles, is an infection by a virus in the paramyxoviridae family. Both are highly contagious airborne viruses. That means they sprea

[unable to retrieve full-text content] 10 ways to tell if your chicken are unwell - FarmKenya Initiative    The Standard

The draft gives a "B" recommendation to screen asymptomatic adults who are at increased risk, such as those who have suppressed immune systems or are taking immunosuppressive medications, or who were born in or previously lived in countries with an increased prevalence of TB. It does not apply to adults with symptoms of TB or to people younger than 18. Overall, the draft is consistent with the task force's 2016 recommendation, which also received a "B" grade. In 2020, the last year for which data is available, more than 71% of all cases of active TB in the United States occurred among people born outside the United States. Compared with active TB, in which patients show clear signs of illness and may be infectious, people with latent TB do not have symptoms or feel sick, and cannot spread TB bacteria to others. While many people with latent TB infection never develop TB, others can become ill weeks or even years after becoming infected. Screening

Haemophilia is a genetic condition that affects the formation of blood clots (pictured). Steve Gschmeissner/Science Photo Library On 22 November, the US Food and Drug Administration (FDA) approved the first gene therapy for the genetic blood-clotting disorder haemophilia B — a one-time treatment that costs US$3.5 million. Hemgenix — developed by the pharmaceutical company CSL Behring, based in King of Prussia, Pennsylvania — uses a modified virus to deliver a gene to the recipient's liver cells. The gene codes for a protein involved in blood clotting called factor IX, which people with the disease are unable to produce. Clinical trial data suggest that the single dose of Hemgenix will provide people with moderate to severe haemophilia with adequate protection from uncontrolled bleeding for eight years, and potentially longer. But the treatment's hefty price tag makes it the most expensive drug in the world. And although it seems to be effective, gen

WHO announced that Dr Jeremy Farrar will become its new Chief Scientist. Currently, Director of the Wellcome Trust, Dr Farrar will join WHO in the second quarter of 2023. Dr Amelia Latu Afuhaamango Tuipulotu will become WHO's Chief Nursing Officer. Previously Minister for Health of the Kingdom of Tonga, and before that Tonga's Chief Nursing Officer, Dr Tuipulotu will join WHO in the first quarter of 2023. As WHO's Chief Scientist, Dr Farrar will oversee the Science Division, bringing together the best brains in science and innovation from around the world to develop and deliver high quality health services to the people who need them most, no matter who they are and where they live. Dr Farrar is a clinician scientist who, before joining Wellcome in 2013, spent 17 years as Director of the Clinical Research Unit at the Hospital for Tropical Diseases in Viet Nam where his research interests were in global health with a focus on emerging infectious diseases. Under Dr Farrar,

Patients with chronic hepatitis B virus (HBV) infection show sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss after 24 weeks of bepirovirsen therapy, according to study findings published in The New England Journal of Medicine . Researchers conducted a phase 2b, randomized, parallel-cohort trial of participants with chronic HBV infection who were receiving or not receiving nucleoside or nucleotide analogue (NA) therapy. Patients (N=457) with chronic HBV infection for more than 6 months were recruited for the B-Clear trial conducted between 2020 and 2022 at 123 sites in 22 countries. Participants were randomly assigned in a 3:3:3:1 ratio to receive either weekly subcutaneous injections of bepirovirsen 300 mg for 24 weeks (n=138; group 1), bepirovirsen 300 mg for 12 weeks followed by 150 mg bepirovirsen for 12 weeks (n=136; group 2), bepirovirsen 300 mg for 12 weeks followed by placebo for 12 weeks (n=136; group 3), or placebo for 12 weeks